Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Angion Biomedica Corp
Astex Pharmaceuticals Inc
BioAxone BioSciences Inc
HitGen LTD
Kadmon Corp LLC
Redx Pharma Plc
Theratrophix LLC
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
ANG-4201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-13148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-2017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-08397 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDX-8087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Metabolic Disorders, Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
Rho Associated Protein Kise 2 (Rho Kise 2 or Rho Associated Coiled Coil Containing Protein Kise 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: BioAxone BioSciences expands patent for treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho kise inhibitors
Dec 03, 2019: Kadmon to present updated data from phase 2 study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition
Nov 19, 2019: Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project including Small Molecule to Inhibit ROCK2 for Fibrotic Diseases
Sep 12, 2019: BioAxone BioSciences announces publication in Translatiol Stroke Research of Cavernous Angioma Disease Research Article
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
Jul 09, 2019: Kadmon doses first patient in phase 2 clinical trial of KD025 in Systemic Sclerosis
Feb 12, 2019: Redx Pharma: New in vivo data suggests ROCK2 has broad potential in fibrosis
Dec 03, 2018: Kadmon announces updated findings from ongoing phase 2 clinical trial of KD025 in cGVHD at ASH Annual Meeting
Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
Nov 01, 2018: Kadmon announces oral presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting
Oct 26, 2018: Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego
Oct 25, 2018: Kadmon initiates pivotal phase 2 trial of KD025 in chronic graft-versus-host disease
Oct 22, 2018: Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego
Oct 17, 2018: FDA grants breakthrough therapy desigtion to Kadmon’s KD025 for chronic graft-versus-host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by BioAxone BioSciences Inc, H2 2019
Pipeline by HitGen LTD, H2 2019
Pipeline by Kadmon Corp LLC, H2 2019
Pipeline by Redx Pharma Plc, H2 2019
Pipeline by Theratrophix LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019